Lucid Diagnostics (LUCD) filed a shelf registration late Wednesday with the Securities and Exchange Commission for the potential secondary sale, 'from time to time,' of up to 37 million of its shares by 2024 convertible note holders.
The company closed the sale of about $22 million in principal amount of Senior Secured Convertible Notes in a private placement in November 2024. The 37 million of its shares potentially sold in secondary offerings refer to 'a reasonable estimate of the maximum number of shares issuable upon conversion of, and in payment of interest on' those notes.
Lucid said it is not selling any of its stock under the shelf registration, and will not receive any proceeds from such a sale.
'The timing and amount of any sales are within the sole discretion' of the secondary sale's stockholders, the company added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.